Janus Henderson Group PLC Cuts Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Janus Henderson Group PLC reduced its position in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 46.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,395,058 shares of the biopharmaceutical company's stock after selling 2,940,177 shares during the period. Janus Henderson Group PLC owned about 1.14% of Amicus Therapeutics worth $31,980,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. Covestor Ltd grew its stake in Amicus Therapeutics by 114.9% in the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock valued at $41,000 after acquiring an additional 2,312 shares during the last quarter. R Squared Ltd purchased a new stake in Amicus Therapeutics during the 4th quarter worth about $79,000. KBC Group NV raised its position in shares of Amicus Therapeutics by 44.4% in the fourth quarter. KBC Group NV now owns 10,154 shares of the biopharmaceutical company's stock valued at $96,000 after buying an additional 3,120 shares during the last quarter. Sciencast Management LP purchased a new position in shares of Amicus Therapeutics during the fourth quarter valued at approximately $100,000. Finally, Stephens Inc. AR purchased a new position in shares of Amicus Therapeutics during the fourth quarter valued at approximately $101,000.

Analysts Set New Price Targets

FOLD has been the subject of several recent analyst reports. Wells Fargo & Company lowered their target price on shares of Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research note on Thursday, February 20th. Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. The Goldman Sachs Group dropped their target price on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research note on Friday, May 2nd. UBS Group raised their price target on Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Finally, StockNews.com cut Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Monday, May 5th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $16.22.

Amicus Therapeutics Trading Up 2.2%

NASDAQ:FOLD traded up $0.14 on Tuesday, hitting $6.56. 836,998 shares of the stock were exchanged, compared to its average volume of 2,817,039. The stock has a fifty day moving average of $7.32 and a 200-day moving average of $8.85. The stock has a market cap of $2.02 billion, a PE ratio of -36.42, a PEG ratio of 1.51 and a beta of 0.64. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01. Amicus Therapeutics, Inc. has a fifty-two week low of $5.81 and a fifty-two week high of $12.65.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.